Ultra Market Research | Asia-Pacific Idiopathic Pulmonary Fibrosis Market
Asia-Pacific Idiopathic Pulmonary Fibrosis Market
Report ID : 710
Category : Therapeutic-Area,Asia-Pacific
No Of Pages : 144
Published on: September 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Asia-Pacific Idiopathic Pulmonary Fibrosis Market
Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) market is expected to experience significant growth over the forecast period. Idiopathic pulmonary fibrosis is a chronic, progressive lung disease characterized by scarring of lung tissue, leading to severe respiratory difficulties. With increasing awareness, advancements in treatment, and an aging population in the Asia-Pacific region, the market for IPF treatments is set to grow.
Idiopathic Pulmonary Fibrosis (IPF) is a type of interstitial lung disease (ILD) with no known cause, resulting in inflammation and fibrosis (scarring) of lung tissues. The disease primarily affects people over 50 years old and is associated with poor prognosis, with many patients living only 3-5 years post-diagnosis. Treatments focus on managing symptoms and slowing disease progression.
Asia-Pacific IPF market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.2% from 2024 to 2032. The growing elderly population, combined with rising healthcare expenditure in key countries like China, Japan, South Korea, and India, will drive demand for advanced IPF therapies. The market size is anticipated to reach USD 450 million by 2032, up from USD 250 million in 2024.
Key Drivers
Aging Population: The Asia-Pacific region has a rapidly aging population, particularly in Japan and China, which increases the prevalence of age-related diseases like IPF.
Increasing Awareness: Healthcare campaigns and initiatives to raise awareness of IPF have resulted in earlier diagnoses, facilitating timely treatment and driving demand for therapeutic options.
Technological Advancements: Ongoing research and innovation in the development of novel therapeutics, such as antifibrotic drugs (Pirfenidone and Nintedanib), offer new opportunities for effective management of IPF symptoms.
Economic Growth & Healthcare Spending: Rising income levels in the Asia-Pacific region, coupled with increased government spending on healthcare infrastructure, create a supportive environment for market expansion.
Market Restraints
High Cost of Treatment: IPF treatments, especially novel therapies, are costly, which could limit their adoption in low- and middle-income countries within the Asia-Pacific region.
Limited Awareness in Rural Areas: While awareness of IPF is increasing, rural populations in countries like India, Indonesia, and Vietnam often face delayed diagnoses and limited access to advanced healthcare facilities.
Adverse Side Effects of Drugs: Antifibrotic drugs, though effective, often have significant side effects, including gastrointestinal issues and liver enzyme abnormalities, which may hinder their widespread adoption.
Opportunities
Development of Biosimilars: With the high cost of current IPF therapies, there is a growing demand for affordable biosimilars, especially in cost-sensitive regions like Southeast Asia and India.
Expansion into Untapped Markets: Countries such as Thailand, Malaysia, and the Philippines represent untapped markets with growing healthcare sectors and increasing focus on respiratory diseases.
Collaborations and Mergers: Key players are collaborating with local firms to expand their reach and strengthen their market position, particularly in Japan, China, and South Korea.
Regional Insights
Japan: Japan is the largest market for IPF treatment in the Asia-Pacific region, driven by a rapidly aging population and a robust healthcare system. The country has been a leader in IPF clinical research and drug approvals.
China: With a significant population and increasing cases of IPF, China is a key market for future growth. Government initiatives to improve healthcare infrastructure and access to novel therapies will fuel market expansion.
India: India’s IPF market is still in its nascent stages, but increasing awareness, along with improving healthcare infrastructure, is expected to drive demand for affordable treatments, particularly biosimilars.
South Korea: South Korea's advanced healthcare system, coupled with strong R&D in pharmaceuticals, makes it a growing market for IPF treatment, with increasing access to cutting-edge therapies.
Major companies operating in the Asia-Pacific IPF market include:
Roche Holding AG: The developer of Esbriet (Pirfenidone), one of the most widely used drugs for IPF, has a strong presence in Japan and other key markets.
Boehringer Ingelheim GmbH: Known for its IPF drug Ofev (Nintedanib), Boehringer Ingelheim is actively expanding its market share in the Asia-Pacific region through strategic collaborations.
FibroGen, Inc.: This company focuses on research for fibrosis and offers potential IPF therapies in collaboration with regional partners.
Cipla Ltd.: A key player in India's pharmaceutical market, Cipla is developing and marketing generic and biosimilar versions of IPF drugs, targeting cost-conscious markets.
Recent Developments
Mergers & Acquisitions: Boehringer Ingelheim and Roche continue to expand their reach in the Asia-Pacific region through strategic partnerships with local companies.
New Drug Approvals: China and Japan have seen an increase in the approval of novel therapies and biosimilars for IPF, which is expected to boost market growth.
Research & Development: Significant investment in R&D for next-generation IPF therapies is underway in Japan and South Korea, focusing on improving treatment efficacy and reducing side effects.
Report Highlights
Asia-Pacific IPF market to grow at a CAGR of 7.2% from 2024 to 2032. Key growth drivers include an aging population, increasing awareness, and advancements in therapy. Japan and China represent the largest markets in the region. Major companies like Roche and Boehringer Ingelheim are leading the market with innovative treatments.
Asia-Pacific IPF market is expected to grow at a CAGR of 7.2% during the forecast period (2024–2032).
Japan, China, and South Korea are the leading markets in the Asia-Pacific region.
High cost of treatment and limited awareness in rural areas are key challenges.
The development of biosimilars and expansion into untapped markets like Southeast Asia offer significant growth potential.
Table of content 1. Introduction 1.1. Report Description 1.2. Research Methodology 1.2.1. Data Mining 1.2.2. Market Modeling and Forecasting 1.2.3. Data Validation 1.2.4. Industry Analysis
4. Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type 4.1. Introduction 4.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate by Drug Type (2021-2030) 4.3. Antifibrotic agents (Pirfenidone, Nintedanib) 4.3.1. Antifibrotic agents (Pirfenidone, Nintedanib) Market Size and Growth Rate (2019- 2030) 4.4. Corticosteroids 4.4.1. Corticosteroids Market Size and Growth Rate (2019- 2030) 4.5. Immunosuppressive Agents 4.5.1. Immunosuppressive Agents Market Size and Growth Rate (2021-2030) 4.6. Endoscopic Suturing 4.6.1. Endoscopic Suturing Market Size and Growth Rate (2021-2030) 4.7. Others 4.7.1. Others Market Size and Growth Rate (2021-2030)
5. Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Route of Administration 5.1. Introduction 5.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate by Route of Administration (2021-2030) 5.3. Oral 5.3.1. Oral Market Size and Growth Rate (2021-2030) 5.4. Intravenous 5.4.1. Intravenous Market Size and Growth Rate (2021-2030)
6. Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel 6.1. Introduction 6.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate by Distribution Channel (2021-2030) 6.3. Hospital Pharmacies 6.3.1. Hospital Pharmacies Market Size and Growth Rate (2021-2030) 6.4. Retail Pharmacies 6.4.1. Retail Pharmacies Market Size and Growth Rate (2021-2030) 6.5. Online Pharmacies 6.5.1. Online Pharmacies Market Size and Growth Rate (2021-2030)
7. Company Profiles 7.1. Roche 7.1.1. Business Overview 7.1.2. Service Portfolio 7.1.3. Strategic Developments 7.1.4. Financial Overview
7.2. Boehringer Ingelheim GmbH 7.2.1. Business Overview 7.2.2. Service Portfolio 7.2.3. Strategic Developments 7.2.4. Financial Overview
7.3. FibroGen, Inc. 7.3.1. Business Overview 7.3.2. Service Portfolio 7.3.3. Strategic Developments 7.3.4. Financial Overview
7.4. Cipla Ltd. 7.4.1. Business Overview 7.4.2. Service Portfolio 7.4.3. Strategic Developments 7.4.4. Financial Overview
8. List of Tables and Figures Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Market Share by Drug Type (2021-2023) Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Market Share by Drug Type (2023-2030) Figure Antifibrotic agents (Pirfenidone, Nintedanib) Market Size and Growth Rate (2021-2030) Figure Corticosteroids Market Size and Growth Rate (2021-2030) Figure Immunosuppressive Agents Market Size and Growth Rate (2021-2030)
Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Market Share by Route of Administration Type (2021-2023) Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Market Share by Route of Administration Type (2023-2030) Figure Oral Market Size and Growth Rate (2021-2030) Figure Intravenous Market Size and Growth Rate (2021-2030)
Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Market Share by Distribution Channel (2021-2023) Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Market Share by Distribution Channel (2023-2030) Figure Hospital Pharmacies Market Size and Growth Rate (2021-2030) Figure Retail Pharmacies Market Size and Growth Rate (2021-2030) Figure Online Pharmacies Market Size and Growth Rate (2021-2030)
Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Market Share by Technology (2021-2023) Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Market Share by Technology (2023-2030) Figure Conventional Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate (2021-2030) Figure Robotic-Assisted Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate (2021-2030) Figure Other Advanced Technologies Market Size and Growth Rate (2021-2030) Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Regions (2021-2023) Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Regions (2023-2030)
Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2021-2023) Table Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2023-2030) Table Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2021-2023) Table Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2023-2030) Table Asia-Pacific Idiopathic Pulmonary Fibrosis by Country (2021-2023) Table Asia-Pacific Idiopathic Pulmonary Fibrosis by Country (2023-2030) Figure China Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate (2021-2030) Table China Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2021-2023) Table China Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2023-2030) Table China Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2021-2023) Table China Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2023-2030) Figure Japan Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate (2021-2030) Table Japan Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2021-2023) Table Japan Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2023-2030) Table Japan Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2021-2023) Table Japan Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2023-2030)
Table South Korea Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2021-2023) Table South Korea Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2023-2030) Table South Korea Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2021-2023) Table South Korea Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2023-2030) Figure India Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate (2021-2030) Table India Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2021-2023) Table India Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2023-2030) Table India Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2021-2023) Table India Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2023-2030)
Figure Australia Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate (2021-2030) Table Australia Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2021-2023) Table India Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2023-2030) Table Australia Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2021-2023) Table Australia Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2023-2030) Figure New Zealand Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate (2021-2030) Table New Zealand Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2021-2023) Table New Zealand Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2023-2030) Table New Zealand Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2021-2023) Table New Zealand Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2023-2030) Table New Zealand Asia-Pacific Idiopathic Pulmonary Fibrosis by Country (2021-2023) Table New Zealand Asia-Pacific Idiopathic Pulmonary Fibrosis by Country (2023-2030) Figure Rest of Asia-Pacific Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size and Growth Rate (2021-2030) Table Rest of Asia-Pacific Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2021-2023) Table Rest of Asia-Pacific Asia-Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type (2023-2030) Table Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2021-2023) Table Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis by Route of Administration (2023-2030)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Asia-Pacific market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Asia-Pacific Idiopathic Pulmonary Fibrosis and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Asia-Pacific Idiopathic Pulmonary Fibrosis Market for the past year and forecasts for the next six years. Asia-Pacific Idiopathic Pulmonary Fibrosis Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Asia-Pacific Idiopathic Pulmonary Fibrosis categories. Market size and forecasts for each major application is provided in the context of Asia-Pacific market. The numbers provided in this report are derived on the basis of demand for Asia-Pacific Idiopathic Pulmonary Fibrosis from different application industries in different regions.
